🟢 Milestone Pharmaceuticals is trading 5% up in pre-market with no confirmed catalyst

Milestone Pharmaceuticals is trading at $0.81, up 5.47%, with no confirmed catalyst identified for its October 14 pre-market gain.

• No new company-specific announcement explaining the move was identified.
• The latest reported company news was October 9, when Milestone announced the first European participant enrolled in its ReVeRA-301 Phase 3 trial; that earlier update does not establish a cause.
• Broader market indicators were mixed and did not show a clear same-direction move explaining the gain.